LTR Pharma (ASX:LTP) said its SPONTAN nasal spray product will be available through TerryWhite Chemmart's pharmacy network in Australia under its earlier distribution agreement with Symbion, according to a Tuesday Australian bourse filing.
TerryWhite Chemmart is a subsidiary of EBOS Group (ASX:EBO, NZE:EBO) alongside Symbion, the filing said.
LTR Pharma developed new commercial packaging for the SPONTAN intranasal spray, designed for pharmacy distribution and incorporating Therapeutic Goods Administration-compliant labeling, patient information materials, and pharmacy-standard barcodes.
The expanded pharmacy rollout will allow the firm to gather real-world data on SPONTAN usage to support its regulatory strategy and preparations for a full commercial launch following regulatory approval in Australia.
Its shares jumped over 38% in recent trading on Tuesday.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。